1. A New Era for Treating Enterococcus faecalis Endocarditis
- Author
-
Francesc Marco, Carlos Cervera, Juan M Pericas, Teresa Ribalta Farres, Carlos Falces, and Asunción Moreno Camacho
- Subjects
Male ,medicine.medical_specialty ,Enterococcus faecalis ,Physiology (medical) ,Internal medicine ,Ampicillin ,medicine ,Humans ,Endocarditis ,Native Valve Endocarditis ,biology ,business.industry ,Aminoglycoside ,Endocarditis, Bacterial ,medicine.disease ,biology.organism_classification ,Anti-Bacterial Agents ,Surgery ,Infective endocarditis ,Vancomycin ,Female ,Gentamicin ,Gentamicins ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Enterococci are the third most common etiologic agent of infective endocarditis worldwide after staphylococci and streptococci and cause 10% to 15% of cases.1 Enterococcal infections are increasingly relevant, especially among the elderly and patients with comorbid conditions in the healthcare setting.2,3 Approximately 90% of cases of enterococcal endocarditis are caused by Enterococcus faecalis , with 3-month history of symptoms before diagnosis.4 The gentamicin dose schedule (3 mg/kg per 24 hours IV …
- Published
- 2013
- Full Text
- View/download PDF